Cellectar Biosciences, Inc.
About Cellectar Biosciences, Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$21.8M
- Total assets
- $15.0M
- Market cap
- $20.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating income
- -$23.0M
- Income tax
- -$6.9M
- Net income
- -$21.8M
- EPS (basic)
- $-8.35
- EPS (diluted)
- $-8.35
Balance sheet
- Total assets
- $15.0M
- Current assets
- $14.0M
- Total liabilities
- $5.1M
- Current liabilities
- $4.7M
- Shareholders’ equity
- $8.5M
Cash flow
- Operating cash flow
- -$23.1M
- Investing cash flow
- -$5.9K
- Financing cash flow
- $13.0M
- Net cash flow
- -$10.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $20.7M
- EPS (diluted)
- $-8.35
- Shares outstanding
- 8.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 19, 2005
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $21.8M.
- Trading 82% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cellectar Biosciences, Inc..
Write a review
News about Cellectar Biosciences, Inc.
News & sentiment via Polygon.io
